BIDDEFORD — Brian Denger is the father of two sons who were diagnosed with the debilitating disease of Duchenne muscular dystrophy.
His older son, Matthew, died in February 2013. The Biddeford High School graduate was attending the University of New England in Biddeford. He was 20.
Brian Denger’s son, Patrick, also has the disease.
Duchenne is the most common of the nine major forms of muscular dystrophy, which causes progressive weakness and degeneration of the skeletal muscles used during voluntary movement. Each year, it affects approximately 3,500 to 6,000 infant boys in the U.S.
Because of his very personal connection with the disease, Brian Denger has become an advocate for finding a cure.
In February, Denger was in Washington, D.C. as a representative of the Parent Project Muscular Dystrophy, an organization devoted to muscular dystrophy research, to lobby for the reauthorization of The Muscular Dystrophy Community Assistance, Research and Education Act.
Known as the MD-CARE Act, the measure, signed into law by President George W. Bush in December 2001, provides funding not only for Duchenne, but also for all forms of muscular dystrophy.
The law expired last year, said Denger, so he hopes Congress will act before the November election to renew it.
“If it’s not passed at the end of the congressional year (in October), we’ll need a new effort with a new Congress,” he said, which will require educating newly elected congressional members and endanger funding for muscular dystrophy research.
Denger said he’s cautiously optimistic that the reauthorization of MD-Care act will pass. However, he said, “If we fail by October, I hope people will champion the effort to rewrite legislation.”
While in Washington, Denger made a special stop at the office of U.S. Sen. Susan Collins, R-Maine. Denger said all of Maine’s congressional representatives have been supportive of the bill. All four, including Collins, Sen. Angus King, I-Maine, Rep. Chellie Pingree, D-Maine, and Rep. Michael Michaud, D-Maine, are co-sponsors of the reauthorization, he said.
But Collins has been the longest and most consistent supporter, said Denger. She was a co-sponsor of the original MD-Care Act in 2001 and its reauthorization in 2008.
She was also an original co-sponsor of the MD-Care Act amendments in 2013.
“I have known the Denger family for many years,” said Collins. “They are passionate advocates for Duchenne muscular dystrophy research and treatment, and I am proud to be their voice in Washington.
“Matthew accomplished so much in his young life, and, because of his dedication and enthusiasm and that of his brother, Patrick, and their parents, we have made considerable progress in the fight against Duchenne and other forms of muscular dystrophy.”
Collins said the lifespan of those with Duchenne MD has increased by about 10 years since the MD-Care Act was passed.
“Reauthorizing the MD-Care Act, which I strongly support, is essential to continuing our investments in research and treatment and maintaining our progress in this important endeavor,” said Collins.
In recognition of the senator’s support, Denger presented one of the many stuffed monkeys collected by Matthew, who had interned in Collins’ Biddeford office for seven years.
Collins plans to display the stuffed animal in her Biddeford office.
— Staff Writer Dina Mendros can be contacted at 282-1535, ext. 324 or dmendros@journaltribune.com.
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less